Navigation Links
Fujifilm Sees Significant Growth of Managed Services Business
Date:11/30/2008

with the needs of teleradiology in mind, the tele-RIS functionality comes in the form of a single (otherwise known as a global) worklist. As the name implies, the single worklist enables radiology groups that read for multiple facilities with disparate PACS to have a single view of all studies they need to interpret. Because all orders and information are driven to one RIS, it creates tremendous efficiencies by eliminating the need for repetitively logging in and out of multiple systems. Having a single platform to read from also aids radiologist workflow by enabling the use of just one integrated RIS/PACS/Reportingplatform, versus having to learn and use as many different systems as there are different hospitals being serviced.

Fujifilm has also added to the Managed Services model through the newly established partnership with Evolved Digital Solutions, Inc. Evolved's RIS customers are actively being converted to Fujifilm's RIS and the Managed Services model, thus assuring that they can gain value from advanced technology they need and expect from an established and growing organization. Just some of the capabilities that the Evolved base will now benefit from include scheduling, billing, mammography tracking, and greater flexibility in communicating with referring physicians.

"From the start Fujifilm has had a clear differentiator by designing Managed Services as a true business model for productivity and growth, and not just as a simple hosting and recovery service," said Yordy. "We're excited about our new capabilities and our strategic partnership, and expect that they will continue to foster the unprecedented growth we've been experiencing."

During the past year the company has expanded the data center two and a half times its original size, and new customer growth is up 130 percent over the previous 12 months. Additionally, bandwidth has been increased ten times to speed the delivery of studies
'/>"/>

SOURCE Fujifilm Medical Systems USA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Fujifilm Receives FDA Approval for Unity SpeedSuite(TM)
2. Fujifilm Introduces Breast Imaging Diagnostic Workstation
3. Thinking Systems Corporation Announces Integration of Its ThinkingPACS(TM) for Molecular Imaging Into Fujifilms Synapse(R) PACS
4. Fujifilm Acquires Information Systems Vendor Empiric
5. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
6. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
7. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
8. Study shows adverse drug events reported to the FDA have significantly increased
9. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
10. Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization
11. Rehabilitation significantly underused after heart attack and bypass surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3Health News:VHI Releases Annual Industry Report - Highlights Hospital, Nursing Facility Efficiency 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 3Health News:MassMutual Recognized as One of America's Healthiest Companies 2Health News:MassMutual Recognized as One of America's Healthiest Companies 3Health News:New research identifies modifiable risk factors for heart disease 2Health News:New research identifies modifiable risk factors for heart disease 3Health News:New research identifies modifiable risk factors for heart disease 4Health News:New research identifies modifiable risk factors for heart disease 5Health News:New research identifies modifiable risk factors for heart disease 6
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Mesa Labs Increases Quarterly Dividend 61255 1Neogen to Ring NASDAQs Closing Bell 14815 1Neogen to Ring NASDAQs Closing Bell 14815 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 1Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 3